AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps

AstraZeneca and Daiichi Sankyo have new data regarding their blockbuster HER2-targeted ADC Enhertu, but they won’t say exactly what’s coming down the pike.

The partners put out word Monday morning that an analysis of a Phase II trial met a “prespecified target for objective response rate and demonstrated durable response” in different types of advanced, HER2-expressing solid tumors in patients who had been heavily pretreated.